Diagnosis, treatment and outcome of glutaric aciduria type I in Zhejiang Province, China

Med Sci Monit. 2011 Jul;17(7):PH55-9. doi: 10.12659/msm.881834.

Abstract

Background: Glutaric aciduria type I (GA I; MIM 231670) is a rare autosomal recessive disorder resulting from glutaryl-CoA dehydrogenase deficiency. This article reports our experience in the diagnosis, treatment and outcome of GA I patients in Zhejiang Province, China.

Material/methods: A total of 129,415 newborns (accounting for approximately one-tenth of the annual births in Zhejiang Province) and 9640 high-risk infants were screened for inborn errors of metabolism in the Neonatal Screening Center of Zhejiang Province during a 3-year period. Tandem mass spectrometry and gas chromatography-mass spectrometry were used for diagnosis of the patients. Dietary modification, carnitine supplementation and aggressive treatment of intercurrent illnesses were adapted for GA I patients.

Results: Three infants were diagnosed with GA I by high-risk screening (detection rate: 1/3,213) and 2 were diagnosed by newborn screening (incidence: 1/64,708). Four patients (3 by high-risk screening and 1 by neonatal screening) undergoing MRI examination showed remarkable changes on T2-weighted image. Four patients accepted timely treatment, and in the patient diagnosed by neonatal screening, treatment was delayed until hypotonia appeared 3 months later. Neuropsychological assessment showed mental and motor retardation in 3 patients after treatment, including the patient diagnosed by neonatal screening.

Conclusions: Individualized timely treatment and close monitoring of GA I patients needs to be optimized in China. Appropriate communication with parents may help to achieve successful management of GA I patients.<br />

Publication types

  • Case Reports

MeSH terms

  • Amino Acid Metabolism, Inborn Errors / diagnosis*
  • Amino Acid Metabolism, Inborn Errors / drug therapy*
  • Amino Acid Metabolism, Inborn Errors / epidemiology*
  • Amino Acid Metabolism, Inborn Errors / genetics
  • Brain Diseases, Metabolic / diagnosis*
  • Brain Diseases, Metabolic / drug therapy*
  • Brain Diseases, Metabolic / epidemiology*
  • Brain Diseases, Metabolic / genetics
  • Carnitine / therapeutic use
  • China / epidemiology
  • Female
  • Gas Chromatography-Mass Spectrometry
  • Genes, Recessive
  • Glutaryl-CoA Dehydrogenase / deficiency
  • Glutaryl-CoA Dehydrogenase / genetics
  • Humans
  • Incidence
  • Infant
  • Infant, Newborn
  • Male
  • Mass Screening
  • Neuropsychological Tests
  • Riboflavin / therapeutic use
  • Tandem Mass Spectrometry
  • Treatment Outcome

Substances

  • Glutaryl-CoA Dehydrogenase
  • Carnitine
  • Riboflavin

Supplementary concepts

  • Glutaric Acidemia I